Artal Group’s Q32 Bio QTTB Stock Holding History

Artal Group’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,556	Closed	-$2.24M	–	117
2018 Q4	$2.24M	Hold	5,556	–	–	0.08%	92
2018 Q3	$2.29M	Hold	5,556	–	–	0.06%	97
2018 Q2	$2.04M	Hold	5,556	–	–	0.04%	94
2018 Q1	$1.87M	Buy	+5,556	New	+$1.87M	0.02%	97

Other funds holding QTTB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's QTTB Position: Q1 2019 in Review

Artal Group sold out of Q32 Bio (QTTB) in Q1 2019, closing a stake of 5,556 shares — an estimated $2.24M sold.

Artal Group first reported a position in QTTB in Q1 2018 and held it in 4 quarters. The position peaked at $2.29M in Q3 2018. 66 funds tracked by Wall St. Rank hold QTTB as of Q1 2019.

Artal Group reported no remaining Q32 Bio position as of Q1 2019 after selling out during the quarter.
Artal Group sold 5,556 Q32 Bio shares in Q1 2019, an estimated $2.24M.
Artal Group first reported a position in Q32 Bio in Q1 2018 and held it in 4 quarters.
Artal Group's Q32 Bio position peaked at $2.29M in Q3 2018.
66 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2019.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.